N-isopentyl-N-phenylbenzamide | 16466-48-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-isopentyl-N-phenylbenzamide
• 英文别名: N-isopentyl-benzanilide；N-Isoamyl-benzanilid；Benzoyl-isoamylanilin；N-Isopentyl-benzanilid；N-(3-methylbutyl)-N-phenylbenzamide
• CAS: 16466-48-1
• 化学式: C₁₈H₂₁NO
• 分子量: 267.371
• InChiKey: IEFIUQSITAAJOF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  [(3-甲基-2-丁烯-1-基)氧基]苯 在 吡啶 、 氢氧化钾 、 乙醇 、 氢溴酸 、 钯 、 苯 作用下， 生成 N-isopentyl-N-phenylbenzamide
  参考文献：
  名称：

  Prevalence of Rheumatic Fever and Rheumatic Heart Disease in Yemen

  摘要：

  这项研究的主要目的是确定也门风湿性心脏病的患病率。在1997年10月至1998年3月期间，对5000名年龄在5至18岁之间的学童（2504名女性和2496名男性）进行了一项前瞻性集群抽样筛查研究。疑似病例接受了心电图、胸部X光和多普勒超声心动图检查。尽管未发现活动性风湿热病例，但有12名女孩和6名男孩患有该疾病，患病率为每千人3.6例，高于邻国的报道。所有确诊和疑似病例每3周按体重给予苄青霉素G，先进行试验剂量。风湿热的预防计划，以及预防链球菌喉部感染，是未来的目标。

  DOI：

  10.1177/021849230100900111

文献信息

• Pd-Catalyzed N-Arylation of Secondary Acyclic Amides: Catalyst Development, Scope, and Computational Study
  作者：Jacqueline D. Hicks、Alan M. Hyde、Alberto Martinez Cuezva、Stephen L. Buchwald

  DOI：10.1021/ja9044357

  日期：2009.11.25

  efficient N-arylation of acyclic secondary amides and related nucleophiles with aryl nonaflates, triflates, and chlorides. This method allows for easy variation of the aromatic component in tertiary aryl amides. A new biaryl phosphine with P-bound 3,5-(bis)trifluoromethylphenyl groups was found to be uniquely effective for this amidation. The critical aspects of the ligand were explored through synthetic, mechanistic

  我们报告了无环仲酰胺和相关亲核试剂与芳基九氟甲磺酸酯、三氟甲磺酸酯和氯化物的有效 ​​N-芳基化。这种方法可以很容易地改变叔芳基酰胺中的芳香族成分。发现具有 P 键合 3,5-(双) 三氟甲基苯基的新联芳基膦对这种酰胺化反应特别有效。通过合成、机械和计算研究探索了配体的关键方面。配体的系统变异揭示了 (1) 与磷相邻的“顶环”芳香碳上的甲氧基和 (2) 两个高度吸电子的 P 键合 3,5-(双) 三氟甲基苯基的重要性. 计算研究表明，配体的缺电子性质对于促进酰胺与 LPd(II)(Ph)(X) 中间体的结合很重要。
• 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors
  申请人：Ennis Michael Dalton

  公开号：US20080194590A1

  公开（公告）日：2008-08-14

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , X 4 , X 6 , X 2k , R 2l , R 4 , R 5 , and R 6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明揭示了化合物及其药用可接受盐，其中该化合物具有公式（I）的结构，其中A1，A2，A3，A4，A5，A6，A7，A8，X4，X6，X2k，R2l，R4，R5和R6如本发明详细描述中所定义。还揭示了相应的药物组合物、治疗方法、合成方法和中间体。
• 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors
  申请人：Ennis Michael Dalton

  公开号：US20080200475A1

  公开（公告）日：2008-08-21

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: (I) wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , X 4 , X 6 , R 2a , R x , R 4 , R 5 , and R 6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明公开了化合物及其医药上可接受的盐，其中所述化合物具有以下结构式I：(I)，其中A1，A2，A3，A4，A5，A6，A7，A8，X4，X6，R2a，Rx，R4，R5和R6如发明详细说明中所定义。本发明还公开了相应的制药组合物、治疗方法、合成方法和中间体。
• 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors
  申请人：Ennis Michael Dalton

  公开号：US20080176857A1

  公开（公告）日：2008-07-24

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , X 4 , X 6 , R 2 , R 4 , R 5 , and R 6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明揭示了化合物及其药物可接受的盐，其中化合物具有公式I的结构：其中A1、A2、A3、A4、A5、A6、A7、A8、X4、X6、R2、R4、R5和R6如本发明详细描述中所定义。本发明还揭示了相应的药物组合物、治疗方法、合成方法和中间体。
• Prevalence of Rheumatic Fever and Rheumatic Heart Disease in Yemen
  作者：Abdul Nasser Al-Munibari、Thabet Mohsen Nasher、Siddig Ahmed Ismail、El-Daw Ahmed Mukhtar

  DOI：10.1177/021849230100900111

  日期：2001.3

  The major aim of this study was to determine the prevalence of rheumatic heart disease in Yemen. Between October 1997 and March 1998, a prospective cluster-sampling screening study was carried out on 5000 schoolchildren (2504 female and 2496 male), aged 5 to 18 years. Suspected cases were subjected to electrocardiography, chest radiography, and Doppler echocardiography. Although no case of active rheumatic fever was found, 12 girls and 6 boys were affected by the disease, giving a prevalence of 3.6 per 1000, which is higher than that reported from neighboring countries. All confirmed and suspected cases were given penicillin G benzathine every 3 weeks, according to body weight, after a test dose. Prevention programs for rheumatic fever, together with prevention of streptococcal throat infections, are goals for the near future.

  这项研究的主要目的是确定也门风湿性心脏病的患病率。在1997年10月至1998年3月期间，对5000名年龄在5至18岁之间的学童（2504名女性和2496名男性）进行了一项前瞻性集群抽样筛查研究。疑似病例接受了心电图、胸部X光和多普勒超声心动图检查。尽管未发现活动性风湿热病例，但有12名女孩和6名男孩患有该疾病，患病率为每千人3.6例，高于邻国的报道。所有确诊和疑似病例每3周按体重给予苄青霉素G，先进行试验剂量。风湿热的预防计划，以及预防链球菌喉部感染，是未来的目标。